[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Massachusetts Eye and Ear Infirmary\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":586},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,23,0,[8,41,73,102,133,155,181,207,237,263,292,313,341,362,392,412,426,441,465,489,515,544,566],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":30,"lastUpdatePostDateStruct":31,"startDateStruct":34,"completionDateStruct":36,"leadSponsor":38,"locationsCount":4},"100548778","phase-1-the-safety-and-efficacy-of-intravitreal-topotecan-for-the-treatment-of-proliferative-vitreoretinopathy-100548778",false,"NCT06425419","The Safety and Efficacy of Intravitreal Topotecan for the Treatment of Proliferative Vitreoretinopathy","Inclusion Criteria:\n\n* Patients \\> 18 years old\n* Patients presenting with retinal detachment due with PVR (grade C or higher) or retinal detachment associated with open globe trauma\n* Patients undergoing vitrectomy or vitrectomy with scleral buckle as part of standard care.\n\nExclusion Criteria:\n\n* Patient unable to give consent\n* Patient unable to follow-up\n* Females of childbearing age who are pregnant at the time of recruitment. A pregnancy test will be done to all women of ages 18-55 prior to surgery to ensure they are not pregnant at the time of recruitment.\n* Patients with a history of tractional or exudative retinal detachment.\n* Patients with other planned ocular surgery following PPV\n* Active or chronic or recurrent uncontrolled ocular or systemic disease\n* Active or history of chronic or recurrent inflammatory eye disease\n* Diagnosis of severe nonproliferative or proliferative diabetic retinopathy or vasoproliferative disease in the operative eye\n* Signs of ocular infection at presentation in either eye\n* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively\n* No Light Perception vision in the operative eye\n* Failure to achieve intraoperative reattachment\n* Patient with silicone oil instilled in the operative eye at time of presentation",true,"ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of this clinical trial is to evaluate the safety and efficacy of intravitreal topotecan for the treatment of patients with rhegmatogenous retinal detachment due to proliferative vitreoretinopathy (PVR) or resulting from an open globe injury, and compare the outcomes to those who do no receive intravitreal topotecan. The main objectives it aims to achieve are:\n\n* to study the safety profile of intravitreal topotecan in the treatment of PVR\n* to evaluate the efficacy of intravitreal topotecan in treating PVR.\n\nPost-consent, participants will:\n\n* undergo vitrectomy (with or without scleral buckle) as part of standard treatment for retinal detachment.\n* receive intravitreal topotecan at the time of surgery, post-operative day 7 and post-operative day 28 (if randomized to receive the medication)\n* come in at post-operative day 1, 7, 28, 56, 84, 126 and 168 to undergo a complete ophthalmic exam along with a fundus photography and optical coherence tomography of the macula, have their intraocular pressure and visual acuity measured and their adverse events monitored, if any.\n\nResearchers will compare participants who receive intravitreal topotecan for PVR to those who do not to see if there is a significant variability in recurrence of retinal detachment, rate of retinal reattachment and PVR grade 6 months after surgery.",[26,27,28],"Proliferative Vitreoretinopathy","Proliferative Vitreo-Retinopathy","Rhegmatogenous Retinal Detachment","NOT_YET_RECRUITING","2026-06-30",{"date":32,"type":33},"2026-07-02","ACTUAL",{"date":35,"type":20},"2026-09-01",{"date":37,"type":20},"2028-09-01",{"name":39,"class":40},"Massachusetts Eye and Ear Infirmary","OTHER",{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":45,"acronym":46,"eligibilityCriteria":47,"healthyVolunteers":15,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":21,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":72},"100464743","phase-4-dropless-pars-plana-vitrectomy-study-100464743","NCT05331664","Dropless Pars Plana Vitrectomy Study","DVS","Inclusion Criteria:\n\n* Primary rhegmatogenous retinal detachment (mac-on or mac-off) requiring pars plana vitrectomy (23, 25 and 27-gauge)\n\nExclusion Criteria:\n\n* Need for concomitant lensectomy or cataract surgery\n* Pars plana vitrectomy taking place more than seven days after the initial diagnosis\n* History of any prior vitreoretinal surgery (excluding laser surgery) in surgical eye\n* History of previous retinal detachment in surgical eye\n* History of ocular incisional surgery within six months of surgery (excluding laser surgery) in surgical eye\n* History of ocular laser surgery within 1 month in surgical eye\n* History of intravitreal injection within 1 month in surgical eye\n* Diagnosis of glaucoma or intraocular pressure more than 21 mmHg in either eye\n* Active or chronic or recurrent uncontrolled ocular or systemic disease\n* Active or history of chronic or recurrent inflammatory eye disease\n* Previous history of steroid response\n* Current treatment with oral, topical, or intravitreal corticosteroids\n* Presence of proliferative vitreoretinopathy at the time of diagnosis\n* Presence of giant retinal tear at the time of diagnosis\n* Diagnosis of proliferative diabetic retinopathy\n* Anterior chamber inflammation on presentation in either eye\n* Signs of ocular infection at presentation in either eye\n* Acute external ocular infections\n* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively\n* Inability to use or apply topical eye drops\n* Requirement for silicone oil as a tamponade agent\n* Individuals with impaired decision-making capacity\n* Non-English-speaking subjects","40 Years",{"count":50,"type":20},168,[52],"PHASE4","To demonstrate that intraoperative use of subtenon triamcinolone acetonide at the time of surgery without postoperative eye drops is non-inferior to the regimen of postoperative eye drops following primary pars plana vitrectomy for retinal detachment.",[28],[56,57,58,59,60,61,62],"Vitrectomy","Dropless","Sub-tenon steroids","Postoperative","Inflammation","Randomized clinical trial","Non-inferiority trial","RECRUITING","2026-06-23",{"date":66,"type":33},"2026-06-26",{"date":68,"type":33},"2022-07-25",{"date":70,"type":20},"2027-01-30",{"name":39,"class":40},1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":15,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":96,"completionDateStruct":98,"leadSponsor":100,"locationsCount":101},"100569002","testing-effectiveness-of-a-stochastic-noise-stimulator-to-immediately-improve-balance-and-gait-100569002","NCT06688578","Testing Effectiveness of a Stochastic Noise Stimulator to Immediately Improve Balance and Gait","Improvements in Balance and Gait Using a Stochastic Noise Stimulator: Short Term Response","Inclusion Criteria Older (ages 60+) and younger (aged 21-59) participants with no significant health history will be recruited from the community.\n\nExclusion Criteria\n\nAny person with a self-reported history of:\n\n* impaired proprioception\n* significant eye problems\n* neuromuscular disease\n* seizure\n* stroke\n* unmedicated diabetes\n* cardiovascular disease (except controlled hypertension)\n* renal disease or electrolyte imbalance\n* orthopedic disorders such as severe neck or back pain\n* uncontrolled high blood pressure (200\u002F110 or greater)\n* implanted electronic devices (pacemakers, defibrillators, implanted pumps or stimulator devices, cochlear, etc.)\n* psychotic medications or current psychotic symptoms\n* Any other psychiatric condition requiring hospitalization since 1991\n* recent history of alcohol or drug abuse within the past 6 months\n* inability to stand unassisted for 30 seconds or walk unassisted for 6 minutes","21 Years",{"count":82,"type":20},120,[84],"NA","The goal of this intervention study is to determine if a new electronic stimulation device, similar to a TENS can improve balance and make walking easier in older individuals with reduced balance function. The main question aims to answer the following:\n\nCan using the device improve walking speed in older individuals?\n\nParticipants will be asked to perform a number of tasks while wearing the device:\n\nWalk for 6 minutes\n\n* Stand in place while having balance measured (eyes open and closed)\n* Stand on a foam block while having balance measured (eyes open and closed)\n* Sit in a chair that will tilt +\u002F- 20 degrees while wearing goggles that take videos of the participants eyes.",[87,88],"Vestibular Disorder","Aging",[90,91,92,93],"Balance and Gait","Stochastic Noise Stimulator","Neural degeneration","neuromodulation","2026-06-19",{"date":64,"type":33},{"date":97,"type":20},"2026-09-25",{"date":99,"type":20},"2027-05-31",{"name":39,"class":40},2,{"id":103,"slug":104,"hasResults":11,"nctId":105,"briefTitle":106,"officialTitle":107,"acronym":4,"eligibilityCriteria":108,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":110,"targetDuration":4,"studyType":21,"phases":112,"briefSummary":113,"conditions":114,"keywords":118,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":125,"lastUpdatePostDateStruct":126,"startDateStruct":128,"completionDateStruct":130,"leadSponsor":132,"locationsCount":72},"100640814","spatial-orientation-navigation-and-neuropsychologic-function-in-patients-with-vestibular-implant-100640814","NCT07627087","Spatial Orientation, Navigation, and Neuropsychologic Function in Patients With Vestibular Implant","Vestibular Implant Tested in Patients With Peripheral Vestibular Damage: Effects on Spatial Orientation, Navigation, and Neuropsychologic Function","1. Patients receiving vestibular implants at UNIGE:\n\n   Their inclusion criteria are defined as follows:\n   * Deaf, scheduled for CI surgery\n   * Minimum of five year history of documented absence of bilateral auditory and vestibular function, based on review of their audiograms and vestibular tests.\n   * Vestibular testing consistent with BVL\n   * No neurologic disease. note: these patients are recruited and implanted by the group at the University of Geneva Hospital (UNIGE) as part of their ongoing research. The study team are not involved in any way with the decision to surgically implant patients with cochlear or vestibular implants, nor are the researchers involved in any way with pre- or post-operative clinical care. The researchers only involvement is to perform the cognitive tests before, during, and after relatively short periods of stimulation using the vestibular implant (VI)\n2. Vestibular patients tested at MEE: vestibular testing consistent with unilateral or bilateral vestibular damage.\n\nBoth aspects of the study share the same exclusion criteria:\n\nExclusion Criteria:\n\n* No known neurologic or otologic disease other than the vestibular and auditory deficits noted above.\n* Pregnancy. Pregnant women and women up to 4 months postpartum will be excluded because of the known effects and unknown potential effects of pregnancy on sensory function.\n* Body weight \\>250 lbs (due to motion device safety limits)\n* The chronic use of vestibular suppressant medication (benzodiazepine, antihistamine, anticholinergic)\n* Inability to stand or walk unassisted.\n* Blindness.\n* Unstable medical condition.\n* Orthopedic or musculoskeletal injuries\u002Fconditions that affect gait or balance.\n* Ongoing neck or spinal pain\u002Finjuries or recent history of neck or spinal surgery\n* Amputation, musculoskeletal deformity, or significant leg-length discrepancy\n* A history of severe head trauma.\n* Any major psychiatric disorder (e.g., psychosis, schizophrenia, panic disorder), not including anxiety or depression.\n* Severe heart or pulmonary conditions\n* Active cancer for which chemo-\u002Fradiation therapy is being received.","80 Years",{"count":111,"type":20},20,[84],"The vestibular system, located in the inner ear, provides information to the brain information about how head acceleration and orientation relative to gravity. Damage to the vestibular system is usually permanent and can contribute to a lower quality of life. The goal of this research is to to examine how vestibular implants (VI) may improve performance of cognitive tasks in patients with severe vestibular damage. These higher-level cognitive behaviors include (1) orientation relative to gravity, (2) navigation, and (3) neuropsychologic function. VI patients will be tested in these three cognitive domains across study sessions: pre-stimulation (VI implanted but stimulation OFF), following chronic stimulation (12 days, VI-ON), and then again 1 month later with the VI turned off. There will be both \"true\" stimulation experiments during which the VI will provide motion-modulated stimulation and also \"placebo\" stimulation (no motion cues, tonic stimulus). The order of these experiments will be randomized and separated by 3 months. Researchers will compare VI data in the three cognitive domains (spatial orientation, navigation, \\& neuropsychologic function) with control data from non-implanted bilateral vestibular loss (BVL) and unilateral vestibular loss (UVL) patients and normal subjects.",[115,116,117],"Vestibular Dysfunction","Bilateral Vestibular Loss","Vestibular Implant",[119,120,121,122,123,124],"bilateral vestibular loss","vestibular implant","neuropsychologic function","cognitive function","spatial orientation","navigation","2026-05-30",{"date":127,"type":33},"2026-06-04",{"date":129,"type":33},"2026-01-22",{"date":131,"type":20},"2029-07-31",{"name":39,"class":40},{"id":134,"slug":135,"hasResults":11,"nctId":136,"briefTitle":137,"officialTitle":137,"acronym":4,"eligibilityCriteria":138,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":21,"phases":142,"briefSummary":143,"conditions":144,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":72},"100589915","improving-clinical-efficiency-by-reducing-scheduled-follow-ups-using-cochlear-americas-population-mean-mapping-strategy-100589915","NCT06960616","Improving Clinical Efficiency by Reducing Scheduled Follow-ups Using Cochlear America's Population Mean Mapping Strategy","Inclusion Criteria:\n\n* Postlingually deafened\n* Adults (18+)\n* New cochlear implant recipients with Cochlear Americas devices; identified prior to activation\n* Able to perform follow-up testing tasks (repeating words\u002Fsentences, indicating they heard a sound stimulus, completing questionnaires)\n* English speakers\n\nExclusion Criteria:\n\n* Patients who select other cochlear implant manufactured devices\n* Pre-lingually deafened\n* Multiple disabilities\n* Unable to perform follow-up testing tasks (repeating words\u002Fsentences, indicating they heard a sound stimulus, completing questionnaires)\n* Non-English speakers\n* Children under the age of 18","85 Years",{"count":141,"type":20},48,[84],"The study is about the importance of each follow-up visit after activating a new cochlear implant in addition to evaluating the effectiveness and efficiency of a new programming strategy from Cochlear Americas. Investigators are looking for patients who have recently selected Cochlear Americas as their cochlear implant manufacturer of choice for their upcoming surgery. The aim of this study is to determine if 1) patient outcomes remain stable when reducing follow-up appointments and 2) Cochlear's population mean mapping can produce similar outcomes with patients while additionally reducing appointment times. The hypothesis is that using population mean mapping and reducing the number of follow-up visits after activation will yield similar performance outcomes to a standard of care while decreasing the length of appointment times and number of appointments needed for each patient.",[145,146],"Deafness","Cochlear Hearing Loss","2026-05-18",{"date":149,"type":33},"2026-05-20",{"date":151,"type":33},"2024-02-27",{"date":153,"type":20},"2027-02-26",{"name":39,"class":40},{"id":156,"slug":157,"hasResults":11,"nctId":158,"briefTitle":159,"officialTitle":160,"acronym":4,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":166,"conditions":167,"keywords":169,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":72},"100622444","phase-2-lactiplantibacillus-plantarum-299v-probiotic-supplementation-in-patients-with-diabetic-macular-edema-100622444","NCT07383701","Lactiplantibacillus Plantarum 299v Probiotic Supplementation in Patients With Diabetic Macular Edema","Lactiplantibacillus Plantarum 299v Probiotic Probiotic Supplementation in Patients With Diabetic Macular Edema","Inclusion Criteria:\n\n* Age of at least 18 years, presence of DME at the current clinical visit\n\nExclusion Criteria:\n\n* Patients with contraindication to probiotic supplement (e.g. prior allergy or GI intolerance and any type of immunocompromised diseases).",{"count":163,"type":20},36,[165],"PHASE2","This pilot prospective, interventional, longitudinal study, aims to evaluate the potential benefits of the probiotic supplement Lactobacillus plantarum 299v in patients with diabetic macular edema (DME).\n\nThe study seeks to address the following questions:\n\n1. Does central macular thickness on optical coherence tomography decrease after 4 months of supplementation?\n2. Is visual acuity improved at 1, 2, 3, and 4 months following initiation of supplementation?\n3. Is the number of anti-VEGF injections reduced following initiation of supplementation?\n\nOutcomes will be compared to a control group, using historic retrospective data.\n\nParticipants will take Lactobacillus plantarum 299v orally twice daily for four months.",[168],"Diabetic Macular Edema",[170,171,172],"diabetic macular edema","Lactiplantibacillus plantarum 299v","probiotic","2026-05-17",{"date":175,"type":33},"2026-05-19",{"date":177,"type":20},"2026-08-01",{"date":179,"type":20},"2027-09-01",{"name":39,"class":40},{"id":182,"slug":183,"hasResults":11,"nctId":184,"briefTitle":185,"officialTitle":186,"acronym":187,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":189,"targetDuration":4,"studyType":21,"phases":191,"briefSummary":192,"conditions":193,"keywords":195,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":206},"100574025","phase-2-excrossv-multi-site-trial-for-vascularized-high-risk-keratoplasty-100574025","NCT06753916","ExCrossV Multi Site Trial for Vascularized High Risk Keratoplasty","Multicenter Clinical Trial to Evaluate the Safety and Efficacy of Ex Vivo Corneal Cross-linking of Donor Corneal Tissue Used for Vascularized High-risk Keratoplasty","ExCrossV","Inclusion Criteria:\n\n* Age 18 and older\n* Willing and able to provide written informed consent\n* Willing and able to comply with study assessments for the full duration of the study\n* Patients undergoing high-risk penetrating keratoplasty, defined as corneal neovascularization (NV) in 1 or more quadrants ≥2 mm from the limbus or extension of corneal NV to the graft-host junction in a previously failed graft\n* Superficial vessels are defined as those within the anterior one-third of the cornea and deep vessels within the posterior two-thirds of the cornea (i.e., deep stroma).\n\nSuperficial CNV involving ≤2 quadrants (equivalent to ≤6 clock hours) without deep CNV are classified as mild. CNV with \\>2 quadrants of superficial vessels (\\>6 clock hours) or 1 quadrant of deep vessels (\\>3 clock hours) as severe (36).\n\nExclusion Criteria:\n\n* History of Stevens-Johnson syndrome or ocular pemphigoid\n* Ocular or periocular malignancy\n* Non-healing epithelial defect of at least 0.5x0.5 mm in host corneal bed lasting ≥6 weeks preoperatively\n* Uncontrolled glaucoma\n* Change in topical corticosteroid regimen within 14 days of transplantation\n* Use of systemic immunosuppressive for indication other than corneal graft rejection\n* Participation in another simultaneous medical investigation or trial\n* Pregnancy (positive pregnancy test) or lactating\n* Pre-menopausal women not using adequate contraception (Reliable intrauterine devices, hormonal contraception or a spermicide in combination with a barrier method)\n* Ocular infection within 30 days prior to study entry.\n* Presence of anterior chamber intraocular lens\n* Active uveitis within 90 days prior to the study entry.\n* No ocular surgery or procedure within 90 days prior to the study entry or concomitant to the study procedure.",{"count":190,"type":20},96,[165],"The main objective of this study is to determine the safety of Ex Vivo Cross Linking (CXL) of donor corneal tissue in participants who have undergone high-risk penetrating keratoplasty.",[194],"Corneal Transplant Failure",[196,197],"Keratoplasty","Cross Linking","2026-04-17",{"date":200,"type":33},"2026-04-21",{"date":202,"type":33},"2025-04-01",{"date":204,"type":20},"2031-01-01",{"name":39,"class":40},12,{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":214,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":217,"conditions":218,"keywords":220,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":229,"lastUpdatePostDateStruct":230,"startDateStruct":232,"completionDateStruct":234,"leadSponsor":236,"locationsCount":72},"100583383","ctdna-in-cutaneous-squamous-cell-carcinoma-100583383","NCT06875609","ctDNA in Cutaneous Squamous Cell Carcinoma","ctDNA Clearance and ctDNA Monitoring Study in Cutaneous Squamous Cell Carcinoma","Post-Operative Cohort\n\nInclusion Criteria:\n\n* Patients with surgically resectable primary CSCC with PNI (\\>0.1mm caliber nerve) or at least 2 high-risk features defined as size \\> 2cm, recurrent CSCC, LVI, immunosuppressed, poorly differentiated, and\u002For invasion \\>6mm\u002Fbeyond subcutaneous fat;\n* Patients with surgically resectable regional metastases not receiving neoadjuvant therapy\n\nExclusion Criteria:\n\n* Patients with Cutaneous Squamous Cell Carcinoma not amenable to surgical resection\n* Patients receiving or undergoing systemic therapies.\n\nNeoadjuvant Cohort\n\nInclusion Criteria:\n\n* Patients with resectable AJCC (8th ed) Stage II, III or IV(M0) CSCC treated with neoadjuvant immunotherapy as part of standard care.\n\nExclusion Criteria:\n\n* Patients ineligible for neoadjuvant treatment.\n\nDefinitive Immunotherapy Cohort\n\nInclusion Criteria:\n\n* Patients with unresectable locally advanced or metastatic CSCC, AJCC (8th ed) Stage II, III, or IV), receiving immunotherapy as part of standard of care.\n\nExclusion Criteria:\n\n* Patients undergoing systemic therapies outside the standard of care or enrolled in conflicting clinical trials.",{"count":215,"type":20},60,"OBSERVATIONAL","The purpose of this study is to test the potential for a liquid biopsy assay to detect residual disease after surgery in patients with cutaneous squamous cell carcinoma as well as the potential for this assay to monitor response to immunotherapy treatment.",[219],"Cutaneous Squamous Cell Carcinoma",[221,222,223,224,225,226,227,228],"Circulating Tumor DNA","CSCC","Skin cancer","Biomarker","ctDNA","Minimal Residual Disease (MRD)","Liquid Biopsy","Advanced Skin Cancer","2026-03-26",{"date":231,"type":33},"2026-03-30",{"date":233,"type":33},"2025-03-24",{"date":235,"type":20},"2029-04-30",{"name":39,"class":40},{"id":238,"slug":239,"hasResults":11,"nctId":240,"briefTitle":241,"officialTitle":242,"acronym":4,"eligibilityCriteria":243,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":139,"enrollmentInfo":244,"targetDuration":4,"studyType":21,"phases":246,"briefSummary":247,"conditions":248,"keywords":251,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":256,"lastUpdatePostDateStruct":257,"startDateStruct":258,"completionDateStruct":260,"leadSponsor":262,"locationsCount":72},"100538335","a-trial-of-hydrus-microstent-versus-goniotomy-100538335","NCT06289491","A Trial of Hydrus Microstent Versus Goniotomy","Randomized Trial of Hydrus Microstent Versus Goniotomy","Inclusion Criteria:\n\n* Visually significant cataract planned for surgery\n* Mild to moderate open-angle glaucoma, including pigmentary glaucoma and pseudoexfoliation glaucoma\n* Mild stage glaucoma includes glaucomatous optic neuropathy and visual field mean deviation better than -6.0 dB, with no points in the central 5 degrees \\\u003C15 dB\n* Moderate stage glaucoma includes: 1) glaucomatous optic neuropathy and visual field mean deviation equal to or worse than -6.0 dB but no worse than -12.0 dB and no central 5 degree points \\\u003C15 dB or 2) mean deviation -12.0 dB or better with 1 central 5 degree point \\\u003C15 dB\n* Medicated IOP between 10 to 31 mm Hg, inclusive, at time of decision for surgery\n* Willing and able to understand and provide informed consent\n* Willing and able to attend postoperative examinations per protocol schedule\n\nExclusion Criteria:\n\n* Prior argon laser trabeculoplasty, laser peripheral iridotomy, incisional glaucoma surgery, or cyclophotocoagulation\n* Selective laser trabeculoplasty within 90 days of study enrollment\n* Iridotrabecular contact for 180 degrees or greater\n* Peripheral anterior synechiae in nasal or inferior angle\n* Best corrected visual acuity worse than 20\u002F200\n* Phacodonesis on pre-operative examination\n* Vitreous in anterior chamber on pre-operative examination\n* Nanophthalmos\n* Anti-platelet and anticoagulant medications other than aspirin 81mg daily\n* Active treatment for another ophthalmic condition in either eye (e.g., anti-VEGF injections, steroids for corneal transplant)\n* Abnormality in study eye that could affect tonometry\n* Glaucoma diagnosis other than the above\n* Normal tension glaucoma\n* Conditions that can cause elevated episcleral venous pressure (e.g., Sturge-Weber syndrome, Graves disease, retrobulbar tumor)\n* History of uveitis in either eye\n* Inability to complete gonioscopy examination\n* Use of oral steroids within 90 days or anticipated use of oral steroids\n* Oral medications that can affect IOP, including oral carbonic anhydrase inhibitors such as acetazolamide and methazolamide\n* History of steroid-associated IOP elevation\n* Medically unfit for attending planned study visits\n* Involvement in another interventional research study",{"count":245,"type":20},243,[84],"The goal of this clinical trial is to evaluate the comparative efficacy and safety of Hydrus Microstent, incisional goniotomy, and excisional goniotomy when combined with cataract surgery in patients with mild and moderate open-angle glaucoma. The main questions it aims to answer are:\n\n* How do the intraocular pressure lowering effects of these three microinvasive glaucoma surgeries compare?\n* How do the safety profiles of these three microinvasive glaucoma surgeries compare?\n\nParticipants will be randomized to one of these three microinvasive glaucoma surgeries in combination with cataract surgery.",[249,250],"Glaucoma","Glaucoma, Open-Angle",[252,253,254,255],"Incisional goniotomy","Excisional goniotomy","Hydrus Microstent","Goniotomy","2026-03-24",{"date":231,"type":33},{"date":259,"type":33},"2025-02-14",{"date":261,"type":20},"2029-04",{"name":39,"class":40},{"id":264,"slug":265,"hasResults":11,"nctId":266,"briefTitle":267,"officialTitle":268,"acronym":4,"eligibilityCriteria":269,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":270,"targetDuration":4,"studyType":21,"phases":272,"briefSummary":273,"conditions":274,"keywords":279,"overallStatus":29,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":72},"100587291","phase-1-subconjunctival-humira-for-boston-keratoprosthesis-100587291","NCT06926478","Subconjunctival Humira for Boston Keratoprosthesis","Clinical Trial to Evaluate Short-term Safety of Subconjunctival Adalimumab in Combination With Type 1 Boston Keratoprosthesis Implantation","Inclusion Criteria:\n\n* Age 18 years or older\n* Individuals eligible for keratoprosthesis surgery, as determined by standard-of-care eligibility criteria\n* Patients with poor prognosis for corneal transplantation, severe corneal opacity and\u002For vascularization\n* Patients with vision worse than 20\u002F200 in the eligible eye, and contralateral eye with vision less than 20\u002F40\n* Patients with intact nasal light projection\n* Willing and able to comply with study plan for the full duration of the study\n* Willing and able to sign a written informed consent\n\nExclusion Criteria:\n\n* Active tuberculosis or untreated latent tuberculosis (e.g., positive interferon-# release assay \\[IGRA\\] test, such as Quantiferon-gold)\n* Untreated active hepatitis B or C infection.\n* Ocular or periocular malignancy and\u002For infection\n* Inability to wear contact lens\n* Pregnancy (positive pregnancy test) or lactating\n* Participation in another interventional study at the time of screening\n* Any of the following baseline lab values\n\n  1. White blood count \\\u003C3500 cells per microliter\n  2. Platelets \\\u003C100,000 per microliter\n  3. Hematocrit \\\u003C30%\n  4. AST or ALT \\>1.5X upper limit normal value\n* Multiple sclerosis or other demyelinating disease\n* Severe uncontrolled infection\n* Moderate to severe heart failure (NYHA class III\u002FIV)\n* Active malignancy\n* History of adalimumab intolerance\n* Pregnancy or lactation\n* Medical problems or drug or alcohol dependence problems sufficient to prevent adherence to treatment and study procedures.\n* As judged by the investigator any patients that are questionable for their suitability in the study",{"count":271,"type":20},8,[23],"This trial is studying the safety and tolerability of receiving an injection of adalimumab (Humira) during the Boston Keratoprosthesis (KPro) surgery.",[275,276,277,278],"Penetrating Keratoplasty","Multiple Graft Failure","Ocular Cicatricial Pemphigoid","Stevens-Johnson Syndrome",[280,281,282,283],"Kpro","Boston Kpro","Keratoprosthesis","Type-1 Boston Kpro","2026-03-23",{"date":286,"type":33},"2026-03-27",{"date":288,"type":20},"2026-06-01",{"date":290,"type":20},"2028-06-01",{"name":39,"class":40},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":297,"eligibilityCriteria":298,"healthyVolunteers":11,"sex":16,"minAge":299,"maxAge":139,"enrollmentInfo":300,"targetDuration":4,"studyType":21,"phases":302,"briefSummary":303,"conditions":304,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":129,"lastUpdatePostDateStruct":306,"startDateStruct":308,"completionDateStruct":310,"leadSponsor":312,"locationsCount":72},"100418941","phase-2-dark-adaptation-as-an-early-indicator-of-response-to-statin-therapy-for-intermediate-amd-100418941","NCT04735263","Dark Adaptation as an Early Indicator of Response to Statin Therapy for Intermediate AMD","DELPHI","Inclusion Criteria:\n\n* All subjects with intermediate AMD diagnosis in one or both eyes will be considered, regardless the severity stage and subtype of disease in the other eye.\n\nHigh-risk iAMD (numerous large, confluent drusen covering ≥ 0.5 disk area, with or without pigmentary changes but having no evidence of GA or CNV) in the study eye\n\nSubjects can have either:\n\n(i) Bilateral high-risk iAMD, or (ii) High-risk iAMD in one eye with GA and\u002For CNV in the fellow eye.\n\nExclusion Criteria:\n\n* Patient previously taking high dose Atorvastatin 80 mg\n* Patients previously taking other statins than high dose atorvastatin, in whom primary care provider (PCP) feels cannot be safely moved to high dose atorvastatin or those in which high dose atorvastatin is deemed contraindicated by PCP\n* Patients with known adverse reaction to statins\n* Patients with severe renal disease or multiple comorbidities\n* Age \\>85 years\n* Pregnancy\n* Patients with concomitant use of cyclosporine\n* Active uveitis;\n* Ocular infection;\n* Any retinopathy other than AMD;\n* Media opacities;\n* Refractive error equal or superior to 6 diopters (spherical equivalent);\n* Any previous retina surgery;\n* Other ocular surgery or intra-ocular procedure in the study eye (injection other than anti angiogenic injection, laser) within the 90 days prior to enrollment","50 Years",{"count":301,"type":20},21,[165],"interventional trial for off label use of high dose atorvastatin 80 mg in intermediate AMD patients and correlate recovery response measured by dark adaptation recovery time with drusen volume reduction measured by SD-OCT",[305],"Age-related Macular Degeneration",{"date":307,"type":33},"2026-01-26",{"date":309,"type":33},"2021-02-04",{"date":311,"type":20},"2028-01-01",{"name":39,"class":40},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":15,"sex":16,"minAge":80,"maxAge":109,"enrollmentInfo":319,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":321,"conditions":322,"keywords":329,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":72},"100289070","brain-networks-in-dystonia-100289070","NCT03042962","Brain Networks in Dystonia","Inclusion Criteria:\n\n* Patients will have clinically documented focal dystonia\n* Unaffected relatives of patients with focal dystonia\n* Healthy controls will be healthy volunteers with a negative history of neurological, laryngeal or psychiatric problems\n* Age from 21 to 80 years.\n* Native English speakers.\n* Right-handedness (based on Edinburgh Handedness Inventory).\n\nExclusion Criteria:\n\n* Subjects who are incapable of giving an informed consent.\n* Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed, which must be negative for participation in the imaging studies.\n* Subjects with past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than dystonia in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases, alcoholism, drug depend-ence; (b) psychiatric problems, such as schizophrenia, major and\u002For bipolar depression, obsessive-compulsive disorder; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis.\n* Patients who are not symptomatic due to treatment with botulinum toxin injections into the laryngeal muscles. The duration of positive effects of botulinum toxin vary from patient to patient but lasts on average for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic prior to entering the study.\n* Patients with other forms of dystonia.\n* Patients who have dystonia symptoms at rest in order to avoid the potential confound of dystonic spasms occurring during the scanning.\n* To avoid the possibility of confounding effects of drugs acting upon the central nervous system, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial intake screening. Those patients who receive medication(s) affecting the central nervous system will be excluded from the study.\n* The patients will be asked whether they have undergone any head, neck, or hand surgeries, which resulted in changes in regional anatomy or innervation. Because brain, hand and laryngeal surgery may potentially lead to the brain structure and function re-organization, all patients with history of brain, hand and\u002For laryngeal surgery will be excluded from the study.\n* Subjects who have tattoos, ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve, etc.) that cannot be removed for the purpose of study participation.",{"count":320,"type":20},141,"To date, there is only limited knowledge about the distinct neural abnormalities that lead to the development of different forms of focal dystonia. The goal of this study is to dissect the pathophysiological mechanisms underlying this clinical phenomenon using multi-level brain network analysis in patients with focal dystonia.",[323,324,325,326,327,328],"Spasmodic Dysphonia","Singer's Dystonia","Writer's Cramp","Musician's Focal Hand Dystonia","Craniofacial Dystonia","Blepharospasm Oromandibular Dystonia",[330,331,332],"dystonia","imaging","genetics","2025-12-01",{"date":335,"type":33},"2025-12-08",{"date":337,"type":33},"2015-08-01",{"date":339,"type":20},"2027-12-31",{"name":39,"class":40},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":15,"sex":16,"minAge":348,"maxAge":4,"enrollmentInfo":349,"targetDuration":4,"studyType":21,"phases":351,"briefSummary":352,"conditions":353,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":354,"lastUpdatePostDateStruct":355,"startDateStruct":357,"completionDateStruct":359,"leadSponsor":361,"locationsCount":101},"100505883","perceptual-consequences-of-cochlear-implant-electrode-neuron-interfaces-100505883","NCT05867173","Perceptual Consequences of Cochlear Implant Electrode-neuron Interfaces","Development and Assessment of Listener-tailored Programming for Cochlear Implant Listeners","Inclusion Criteria:\n\nResearch Subjects with a Cochlear Implant ADULTS Inclusion Criteria\n\n* Adult at least 18 years old\n* Native speakers of American English\n* Wears a cochlear implant manufactured by Advanced Bionics (Clarion Hi-Focus I or newer), Cochlear, or MED-EL\n\nCHILDREN Inclusion Criteria\n\n* Children at least 3 months old\n* Native speakers of American English\n* Wears a cochlear implant manufactured by Advanced Bionics (Clarion Hi-Focus I or newer), Cochlear, or MED-EL\n\n  * For both children and adults with a cochlear implant, some study criteria might pertain to a subset of subjects, such as a specific age at which the subjects developed a hearing loss, or was implanted.\n\nExclusion Criteria:\n\nExclusion for all Cochlear Implant Subjects:\n\n* Inability to provide informed consent\n* Does not meet the inclusion criteria for a specific study protocol, such as age of onset of hearing loss, age of cochlear implantation, duration of deafness, number of active electrodes in the cochlear implant device\n* Unable to carry out the study protocol or tasks required in the study\n\nExclusion for all Normal Hearing Subjects:\n\n* Inability to provide informed consent\n* Hearing loss, or significant history of hearing related issues\n* Unable to carry out the study protocol or tasks required in the study","3 Months",{"count":350,"type":20},200,[84],"Despite the success of cochlear implants, devices surgically placed in the inner ears of patients with severe hearing loss, there remains substantial variability in the overall speech perception outcomes for the children and adults who receive them. The main goals of this project are: i) to improve our understanding of how cochlear implants affect the developing auditory system, ii) apply that knowledge to test new methods for programming children and adults, and iii) to study how long it takes listeners to adapt to new cochlear implant programs over the short- and long-term. The results will improve our understanding of how the deafened auditory system develops with cochlear implant stimulation and advance clinical practice to improve hearing outcomes in cochlear implant listeners.",[145],"2025-11-25",{"date":356,"type":33},"2025-11-26",{"date":358,"type":33},"2022-09-16",{"date":360,"type":20},"2027-03-31",{"name":39,"class":40},{"id":363,"slug":364,"hasResults":11,"nctId":365,"briefTitle":366,"officialTitle":366,"acronym":4,"eligibilityCriteria":367,"healthyVolunteers":15,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":368,"targetDuration":4,"studyType":21,"phases":370,"briefSummary":371,"conditions":372,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":385,"startDateStruct":387,"completionDateStruct":389,"leadSponsor":391,"locationsCount":72},"100463645","clinical-validation-of-dystonianet-deep-learning-platform-for-diagnosis-of-isolated-dystonia-100463645","NCT05317390","Clinical Validation of DystoniaNet Deep Learning Platform for Diagnosis of Isolated Dystonia","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic backgrounds, with age across the lifespan;\n2. Patients will have at least one of the forms of dystonia, including focal dystonia (e.g., laryngeal, cervical, oromandibular, blepharospasm, focal hand, musicians), segmental dystonia, or generalized dystonia;\n3. Patients will have other movement disorders (Parkinson's disease, essential tremor, dyskinesia, myoclonus) and other non-neurological conditions (tic disorders, torticollis, ulnar nerve entrapments, temporomandibular disorders, dysphonia) that mimic dystonic symptoms.\n\nExclusion criteria:\n\n1. Patients who are incapable of giving informed consent;\n2. Patients who are unable to undergo brain MRI due to the presence of certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed or due to pregnancy or breastfeeding at the time of the study.",{"count":369,"type":20},1000,[84],"This research involves retrospective and prospective studies for clinical validation of a DystoniaNet deep learning platform for the diagnosis of isolated dystonia.",[373,374,375,376,377,378,379,380,381,382,383],"Dystonia","Drug Induced Dystonia","Parkinson Disease","Essential Tremor","Dyskinesias","Myoclonus","Tic Disorders","Torticollis","Ulnar Nerve Entrapment","Temporomandibular Joint Disorders","Dysphonia","2025-11-24",{"date":386,"type":33},"2025-12-02",{"date":388,"type":33},"2022-06-01",{"date":390,"type":20},"2028-04-30",{"name":39,"class":40},{"id":393,"slug":394,"hasResults":11,"nctId":395,"briefTitle":396,"officialTitle":396,"acronym":4,"eligibilityCriteria":397,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":398,"targetDuration":4,"studyType":21,"phases":400,"briefSummary":402,"conditions":403,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":406,"startDateStruct":407,"completionDateStruct":409,"leadSponsor":411,"locationsCount":72},"100455915","early-phase-1-understanding-disorder-specific-neural-pathophysiology-in-laryngeal-dystonia-and-voice-tremor-100455915","NCT05216770","Understanding Disorder-specific Neural Pathophysiology in Laryngeal Dystonia and Voice Tremor","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic background;\n2. Age 18-80 years;\n3. Native English speakers;\n4. Right-handed;\n5. Normal cognitive status;\n6. Patients will have laryngeal dystonia or voice tremor;\n7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent;\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;\n3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;\n4. Patients with any other form of dystonia;\n5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;\n6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;\n7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;\n8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;\n9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.",{"count":399,"type":20},165,[401],"EARLY_PHASE1","The researchers will examine functional neural correlates that differentiate between laryngeal dystonia and voice tremor and contribute to disorder-specific pathophysiology using a cross-disciplinary approach of multimodal brain imaging.",[404,323,405],"Laryngeal Dystonia","Tremor",{"date":386,"type":33},{"date":408,"type":33},"2022-03-24",{"date":410,"type":20},"2027-08-31",{"name":39,"class":40},{"id":413,"slug":414,"hasResults":11,"nctId":415,"briefTitle":416,"officialTitle":416,"acronym":4,"eligibilityCriteria":417,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":418,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":419,"conditions":420,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":421,"startDateStruct":422,"completionDateStruct":424,"leadSponsor":425,"locationsCount":72},"100450792","characterization-of-clinical-phenotypes-of-laryngeal-dystonia-and-voice-tremor-100450792","NCT05150106","Characterization of Clinical Phenotypes of Laryngeal Dystonia and Voice Tremor","Inclusion criteria:\n\n1. Males and females of diverse racial and ethnic backgrounds;\n2. Age 18-80 years;\n3. Native English speakers;\n4. Right-handed;\n5. Normal cognitive status;\n6. Patients will have laryngeal dystonia or voice tremor;\n7. Healthy controls will be healthy individuals without neurological, psychiatric or otolaryngological problems.\n\nExclusion criteria:\n\n1. Subjects who are incapable of giving informed consent;\n2. Pregnant or breastfeeding women until a time when they are no longer pregnant or breastfeeding. All women of childbearing potential will have a urine pregnancy test performed before MRI, which must be negative for participation in the imaging studies;\n3. Subjects with a past or present medical history of (a) neurological problems, such as stroke, movement disorders (other than specified LD and VT in the patient groups), brain tumors, traumatic brain injury with loss of consciousness, ataxias, myopathies, myasthenia gravis, demyelinating diseases; (b) psychiatric problems, such as schizophrenia, bipolar depression, obsessive-compulsive disorder, alcoholism, drug dependence; (c) laryngeal problems, such as vocal fold paralysis, paresis, vocal fold nodules and polyps, carcinoma, chronic laryngitis;\n4. Patients with any other form of dystonia;\n5. Patients who have dystonia symptoms at rest or have a presence of mirror dystonia;\n6. Patients who are not symptomatic due to treatment with botulinum toxin injections into the affected muscles. The duration of positive effects of botulinum toxin varies from patient to patient but lasts, on average, for 3-4 months. All patients will be evaluated to ensure that they are fully symptomatic and are at least 3 months post-injection before participation;\n7. To avoid the confounding effect of centrally acting drugs, all study participants will be questioned about any prescribed or over-the-counter medications as part of their initial screening. Those patients who receive medication(s) affecting the central nervous system will be excluded;\n8. Patients will be asked whether they have undergone any head or neck surgery, which resulted in changes in regional anatomy or innervation. Because brain or laryngeal surgery may potentially lead to brain structure and function re-organization, all patients with such a history will be excluded;\n9. Subjects who have certain tattoos and ferromagnetic objects in their bodies (e.g., implanted stimulators, surgical clips, prosthesis, artificial heart valve) that cannot be removed for MRI studies.",{"count":399,"type":20},"The researchers will systematically evaluate current and novel clinical voice assessment tools and measures to elucidate distinct clinical phenotypes of those with laryngeal dystonia and voice tremor.",[404,323,405],{"date":386,"type":33},{"date":423,"type":33},"2022-11-07",{"date":410,"type":20},{"name":39,"class":40},{"id":427,"slug":428,"hasResults":11,"nctId":429,"briefTitle":430,"officialTitle":430,"acronym":4,"eligibilityCriteria":431,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":109,"enrollmentInfo":432,"targetDuration":4,"studyType":21,"phases":433,"briefSummary":434,"conditions":435,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":436,"startDateStruct":437,"completionDateStruct":439,"leadSponsor":440,"locationsCount":72},"100450791","deep-brain-stimulation-in-laryngeal-dystonia-and-voice-tremor-100450791","NCT05150093","Deep Brain Stimulation in Laryngeal Dystonia and Voice Tremor","Inclusion\n\n1. Clinical indications to proceed with DBS implantation, as determined by the clinical multidisciplinary movement disorders board, including: a) definitive diagnosis of essential tremor or dystonia, b) medically refractory disease, c) adequate performance on neuropsychological evaluation as determined by a licensed clinical neuropsychologist.\n2. The ability to comply with test directions, complete pre-operative task training, and provide informed consent.\n3. Age 18-80 years.\n\nExclusion\n\n1\\. Inability to understand or perform the task outlined in the protocol during a pre-surgery training session. 2. Significant hearing loss.\n\n3\\. Cortical venous anatomy that could potentially obstruct ECoG electrode placement, as determined by the surgeon, visualized on pre-op MRI or during surgery.",{"count":82,"type":20},[84],"The goals of this project are 1) to determine the incidence of neurological voice disorders in patients with dystonia and essential tremor undergoing deep brain stimulation (DBS), 2) investigate the neuroimaging and intracranial neurophysiology correlates of voice dysfunction in these subjects, and subsequently 3) determine the effects of DBS on voice function.",[404,323,405,373],{"date":386,"type":33},{"date":438,"type":33},"2022-06-21",{"date":410,"type":20},{"name":39,"class":40},{"id":442,"slug":443,"hasResults":11,"nctId":444,"briefTitle":445,"officialTitle":446,"acronym":447,"eligibilityCriteria":448,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":449,"targetDuration":4,"studyType":21,"phases":451,"briefSummary":452,"conditions":453,"keywords":455,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":384,"lastUpdatePostDateStruct":460,"startDateStruct":461,"completionDateStruct":463,"leadSponsor":464,"locationsCount":72},"100379825","phase-1-therapeutic-contact-lens-drug-delivery-system-tcl-dds-in-patients-with-recurrent-cystoid-macular-edema-100379825","NCT04225611","Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema","Randomized, Prospective, Vehicle-Controlled, Phase I\u002FII Clinical Trial to Evaluate the Safety and Feasibility of a Therapeutic Contact Lens Drug Delivery System (TCL-DDS) in Patients With Recurrent Cystoid Macular Edema","ContactLens","Inclusion Criteria\n\nAdults between the ages of 18 and 85 Willingness to participate in the study and provide informed consent For Phase A, patients who only respond to anti-inflammatory drops (not at the intravitreal steroid injection phase of care yet).\n\nFor Phase B, patients who only respond to steroid intravitreal injections (anti-inflammatory drops are no longer therapeutically working for these patients).\n\nCorneal thickness between 480 and 620 µm in the study eye by anterior segment OCT.\n\nDiagnosis of cystoid macular edema in the study eye defined as macular edema involving the center of the macula (fovea) with one or more of the following OCT characteristics: retinal cysts, retinal thickening, and\u002F or subretinal fluid.\n\nVisual acuity between 20\u002F400 and 20\u002F25 in the study eye, measured by pinhole VA.\n\nRetinal thickness above 300 µm as measured by OCT in the 1mm central macular subfield of the study eye at screening as determined by the investigator History of positive response to topical or intraocular steroid treatment defined as 50 µm thinning in response to steroid treatment in the study eye within 1 year Recurrence of cystoid macular edema in the study eye\n\nPatients who have received intravitreal triamcinolone acetonide in the study eye must satisfy the following:\n\nThe most recent dose was at least 8 weeks prior to screening No treatment-related adverse event was seen that, in the opinion of the investigator, has the potential to worsen or reoccur with study treatment.\n\nFemale patients of childbearing potential must have a negative urine pregnancy test at the enrollment (day 0) visit (repeat at day 0 if greater than 14 days past Screening Visit) Aphakia or pseudophakia in the study eye\n\nExclusion Criteria\n\nSystemic Renal failure requiring hemodialysis or peritoneal dialysis within 6 months prior to screening Use of systemic steroids (e.g., oral, intravenous, intra-articular, epidural, intrabursal, inhaled, or intranasal) within 1 month prior to the qualification\u002Fbaseline visit or anticipated use at any time during the study Use of oral carbonic anhydrase inhibitor within 1 month of screening Use of immunosuppressants, immunomodulators, antimetabolites and\u002For alkylating agents within 6 months prior to screening or anticipated use at any time during the study Known allergy or hypersensitivity to the study medication or its components Medical history positive for HIV Any condition (including inability to read visual acuity charts or language barrier) which precludes patient's ability to comply with study requirements including completion of the study Female patients who are pregnant, nursing, or planning a pregnancy, or who are of childbearing potential and not using a reliable means of contraception Participation in an investigational drug or device study within the 30 days prior to screening Patient has a condition or is in a situation which, in the Investigator's opinion, may put the patient at significant risk, may confound the study results, or may interfere significantly with the patient's participation in the study\n\nBoth Eyes Contraindication to pupil dilation in either eye Any active ocular infection (i.e., bacterial, viral, parasitic, or fungal) in either eye at screening History of central serous chorioretinopathy in either eye\n\nHistory of IOP elevation in response to steroid treatment in either eye that resulted in any of the following:\n\n≥ 10 mm Hg increase in IOP from screening visit with an absolute IOP ≥ 25 mm Hg required therapy with 3 or more anti-glaucoma medications History of failure to respond positively to a periocular or intravitreal steroid injection in either eye.\n\nStudy Eye \\[This exclusion has been removed.\\] Any ocular condition in the study eye that in the opinion of the investigator would prevent a 15-letter improvement in visual acuity (e.g., fibrosis, retinal atrophy, severe macular ischemia, extensive macular laser scarring or atrophy) Any ocular condition in the study eye that in the opinion of the investigator would prevent the eye from wearing a contact lens (e.g., ectropion, lid abnormality, or symblepharon) Use of non-steroidal anti-inflammatory eye drops (NSAID) or steroid drops within 1 month prior to screening Presence of any other condition in the study eye severe enough to prevent improvement in visual acuity despite reduction in macular edema History of advanced glaucoma \u002F optic nerve head change consistent with glaucoma damage, and\u002For advanced glaucomatous visual field loss in the study eye\n\nOcular hypertension in the study eye at screening visit determined by the following:\n\nIOP \\> 25 mm Hg if taking no anti-glaucoma medications Active optic disc or retinal neovascularization in the study eye at screening Active or history of choroidal neovascularization in the study eye Presence of rubeosis iridis in the study eye at screening History of herpetic infection in the study eye or adnexa Media opacity in the study eye at screening that precludes clinical and photographic evaluation (including but not limited to preretinal or vitreous hemorrhage, lens opacity) Intraocular surgery, including cataract surgery, and\u002For laser of any type in the study eye within 30 days prior to screening History of pars plana vitrectomy in the study eye within 3 months prior to screening History of use of intravitreal bevacizumab, ranibizumab or pegaptanib in the study eye within 3 months prior to screening Treated with intravitreal injections of dexamethasone implant 0.7 mg (Ozurdex®) within 6 months of screening History of use of any intravitreal agent in the study eye other than corticosteroid, bevacizumab, ranibizumab, or pegaptanib, or intravitreal doses of triamcinolone acetonide \\> 4mg, bevacizumab \\> 1.25 mg, ranibizumab \\> 0.5 mg, or pegaptanib \\> 0.3 mg within 3 months prior to screening.\n\nExcept at the time of surgery, any periocular depot of steroids to the study eye within 3 months prior to screening Inability to comfortably wear a commercial contact lens (Kontur) that has the same dimensions as the TCL-DDS during a 1 hour run-in period Presence of guttae or descemet's folds in the study eye. Corneal neovascularization with presence of blood vessels 2 mm into the cornea.\n\nNon-study Eye Pinhole score \\\u003C19 letters in the non-study eye at screening visit.",{"count":450,"type":20},6,[23,165],"The main aim of the pilot study is to determine preliminary estimates of the safety, tolerability, and comfort of a dexamethasone-eluting therapeutic contact lens drug delivery system (TCL-DDS) for the treatment of recurrent cystoid macular edema. Secondarily, feasibility of the TCL-DDS system will be investigated.\n\n1. Safety: To establish that a topical dexamethasone delivery system has an acceptable safety profile by determining the incidence and severity of ocular adverse events, as identified by eye examination through day 28 following treatment initiation.\n2. Comfort and tolerability: to establish the subject tolerability and comfort of the TCL-DDS.\n3. Feasibility: To establish- that a topical dexamethasone delivery system is a feasible treatment for recurrent cystoid macular edema.",[454],"Cystoid Macular Edema",[456,457,458,459],"contact lens","drug","cystoid","macular edema",{"date":356,"type":33},{"date":462,"type":33},"2021-03-15",{"date":339,"type":20},{"name":39,"class":40},{"id":466,"slug":467,"hasResults":11,"nctId":468,"briefTitle":469,"officialTitle":470,"acronym":4,"eligibilityCriteria":471,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":472,"targetDuration":4,"studyType":21,"phases":473,"briefSummary":474,"conditions":475,"keywords":476,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":481,"lastUpdatePostDateStruct":482,"startDateStruct":484,"completionDateStruct":486,"leadSponsor":488,"locationsCount":72},"100518681","phase-1-topical-netarsudil-for-the-prevention-of-proliferative-vitreoretinopathy-in-patients-with-retinal-detachment-100518681","NCT06033703","Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Retinal Detachment","Topical Netarsudil for the Prevention of Proliferative Vitreoretinopathy in Patients With Primary Rhegmatogenous Detachments and Retinal Detachment Due to Proliferative Vitreoretinopathy or Open-Globe Injury: A Phase I\u002FII Clinical Trial","The primary rhegmatogenous detachment cohort will have the following selection criteria:\n\nInclusion criteria:\n\n* Patients \\> 18 years old\n* Patients presenting for primary rhegmatogenous retinal detachment repair within 28 days of symptom onset\n* Patients undergoing vitrectomy or vitrectomy with scleral buckle\n\nExclusion criteria:\n\n* Patient unable to give consent\n* Patient unable to follow-up\n* Prior history of retinal detachment incisional surgery in presenting eye\n* Prior history of open globe injury to presenting eye\n* Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery, actively on glaucoma medication\n* Prior history of corneal disease, or history of corneal edema\n* Patient already on topical netarsudil in presenting eye\n* Patient without natural lens or intraocular lens implant (I.e., aphakic patients)\n* Patients with intraocular pressure \\\u003C8mm Hg in operative eye\n* Active or chronic or recurrent uncontrolled ocular or systemic disease\n* Active or history of chronic or recurrent inflammatory eye disease\n* Diagnosis of proliferative diabetic retinopathy\n* Signs of ocular infection at presentation in either eye\n* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively\n* Inability to use\u002F apply topical eye drops\n\nThe proliferative vitreoretinopathy cohort will have the following selection criteria:\n\nInclusion criteria:\n\n* Patients \\> 18 years old\n* Patient presenting with retinal detachment due with proliferative vitreoretinopathy (grade C or higher) or retinal detachment associated with open globe trauma\n* Patients undergoing vitrectomy or vitrectomy with scleral buckle\n\nExclusion criteria:\n\n* Patient unable to give consent\n* Patient unable to follow-up\n* Prior history of glaucoma surgery to presenting eye I.e., Status post trabeculectomy, Ahmed tube placement, minimally invasive glaucoma surgery\n* Patient already on topical netarsudil in presenting eye\n* Patients with intraocular pressure \\\u003C8mm Hg in operative eye\n* Active or chronic or recurrent uncontrolled ocular or systemic disease\n* Active or history of chronic or recurrent inflammatory eye disease\n* Diagnosis of severe nonproliferative or proliferative diabetic retinopathy or vasoproliferative disease in operative eye\n* Signs of ocular infection at presentation in either eye\n* Known or suspected sensitivity or allergy to any of the medications used in the operation or postoperatively\n* Inability to use\u002F apply topical eye drops\n* No Light Perception vision in operative eye\n* Failure to achieve intraoperative reattachment",{"count":141,"type":20},[23,165],"This study has two main objectives. The first objective is to study the pharmacokinetics of topical netarsudil administration in the posterior segment of the eye, where netarsudil must exert its effect in order to prevent formation of tractional membranes.\n\nThe second objective is to assess the safety profile of topical netarsudil in the pre- and post-operative periods. A secondary objective of the study is to begin to assess signs of efficacy in preventing formation of tractional membranes post-operatively.",[28,26],[56,477,478,479,480],"Netarsudil","Pharmacokinetics","Safety","Efficacy","2025-10-24",{"date":483,"type":33},"2025-10-28",{"date":485,"type":33},"2025-01-14",{"date":487,"type":20},"2026-12",{"name":39,"class":40},{"id":490,"slug":491,"hasResults":11,"nctId":492,"briefTitle":493,"officialTitle":493,"acronym":4,"eligibilityCriteria":494,"healthyVolunteers":11,"sex":16,"minAge":80,"maxAge":4,"enrollmentInfo":495,"targetDuration":4,"studyType":21,"phases":497,"briefSummary":498,"conditions":499,"keywords":501,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":507,"lastUpdatePostDateStruct":508,"startDateStruct":510,"completionDateStruct":512,"leadSponsor":514,"locationsCount":72},"100396298","phase-2-targeting-reactive-oxygen-species-production-as-a-novel-therapeutic-in-fuchs-endothelial-corneal-dystrophy-100396298","NCT04440280","Targeting Reactive Oxygen Species Production as a Novel Therapeutic in Fuch's Endothelial Corneal Dystrophy","Inclusion Criteria:\n\n1. Male or female ≥21 years of age at time of surgical evaluation.\n2. Diagnosis of advanced FECD and visually significant cataract\n3. Indication for DMEK (Descemet Membrane Endothelial Keratoplasty) with concurrent cataract surgery\n4. Written informed consent obtained from subject and ability for subject to comply with the requirements of the study.\n5. Willingness and ability to adhere to medication regimen\n\nExclusion Criteria:\n\n1. Pregnant, breastfeeding, or unwilling to practice birth control during participation in the study.\n2. History of prior intraocular surgery in study eye including cataract, glaucoma and\u002For retina surgery\n3. History of other corneal diseases, such as severe dry eye, corneal scars, pseudophakic bullous keratopathy, corneal degenerations, corneal infections\n4. Use of ocular prescription medications except for lubricants, hyperosmotic agents, or ocular hypotensive agents\n5. History of ocular surface infection within the past 30 days\n6. Use of systemic, inhalational, or topical N-Acetylcysteine within the past 30 days\n7. History of intolerance to topical N-Acetylcysteine\n8. Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.\n\n   \\-",{"count":496,"type":20},45,[165],"This protocol will investigate whether topical application of N-acetyl cysteine (NAC) eye drops decreases oxidative stress and confers cytoprotection in patients with FECD.",[500],"Fuchs Endothelial Corneal Dystrophy",[502,500,503,504,505,506],"Fuchs","oxidative stress","N-Acetylcysteine ophthalmic drops","Descemet Membrane Endothelial Keratoplasty","DMEK","2025-09-23",{"date":509,"type":33},"2025-09-29",{"date":511,"type":33},"2020-09-16",{"date":513,"type":20},"2027-04-30",{"name":39,"class":40},{"id":516,"slug":517,"hasResults":11,"nctId":518,"briefTitle":519,"officialTitle":520,"acronym":4,"eligibilityCriteria":521,"healthyVolunteers":11,"sex":16,"minAge":522,"maxAge":109,"enrollmentInfo":523,"targetDuration":4,"studyType":21,"phases":524,"briefSummary":525,"conditions":526,"keywords":532,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":538,"lastUpdatePostDateStruct":539,"startDateStruct":540,"completionDateStruct":542,"leadSponsor":543,"locationsCount":72},"100395123","feasibility-tests-for-various-prism-configurations-for-visual-field-loss-100395123","NCT04424979","Feasibility Tests for Various Prism Configurations for Visual Field Loss","Visual Field Expansion Through Innovative Multi-Periscopic Prism Design","Inclusion Criteria:\n\n* Visual field loss, either peripheral field loss or hemianopic field loss\n* Visual acuity of at least 20\u002F50 in the better eye\n* In sufficiently good health to be able to complete sessions lasting 2-4 hours\n* Able to independently walk short distances\n* Able to give voluntary, informed consent\n* Able to speak English\n\nExclusion Criteria:\n\n* Any physical or mental impairments, including cognitive dysfunction, balance problems or other deficits that could impair the ability to walk or use the prism spectacles\n* A history of seizures in the last 6 months\n* Hemispatial neglect (subjects with hemianopic field loss only)","7 Years",{"count":111,"type":20},[84],"The investigators will develop and test different configurations of high-power prisms to expand the field of vision of patients with visual field loss to assist them with obstacle detection when walking. The study will involve multiple visits (typically four) to Schepens Eye Research Institute for fitting and testing with the prism glasses. The overall objective is to determine best designs and fitting parameters for implementation in prism devices for future clinical trials.",[527,528,529,530,531],"Hemianopia, Homonymous","Tunnel Vision","Visual Field Defect, Peripheral","Visual Field Constriction Bilateral","Visual Field Defect Homonymous Bilateral",[533,534,535,536,537],"Visual field expansion","Prisms","Hemianopsia","Tunnel vision","Visual field loss","2025-09-22",{"date":507,"type":33},{"date":541,"type":33},"2020-11-06",{"date":487,"type":20},{"name":39,"class":40},{"id":545,"slug":546,"hasResults":11,"nctId":547,"briefTitle":548,"officialTitle":549,"acronym":550,"eligibilityCriteria":551,"healthyVolunteers":11,"sex":16,"minAge":48,"maxAge":4,"enrollmentInfo":552,"targetDuration":4,"studyType":21,"phases":554,"briefSummary":555,"conditions":556,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":557,"lastUpdatePostDateStruct":558,"startDateStruct":560,"completionDateStruct":562,"leadSponsor":564,"locationsCount":565},"100583901","the-glaucoma-and-retinopathy-screening-study-100583901","NCT06882356","The Glaucoma and Retinopathy Screening Study","The Glaucoma and Retinopathy Screening Study (GRaSS)","GRaSS","* Individuals with diabetes undergoing AI-based screening for diabetic retinopathy using the LumineticsCore (Digital Diagnostics) system for clinical care at primary care centers.\n* Individuals who are able and willing to provide informed consent for participation in the study.",{"count":553,"type":20},2000,[84],"The goal of this clinical trial is to learn if a new screening approach including an artificial intelligence algorithm that analyzes fundus photographs, measurement of eye pressure and visual field testing works to screen for glaucoma.\n\nParticipants will:\n\nHave an image of their fundus (back of the eye) taken as part of their diabetic eye screening Have a measurement of their eye pressure If needed, have a test of their side vision using a headset",[249],"2025-08-26",{"date":559,"type":33},"2025-08-28",{"date":561,"type":33},"2025-07-16",{"date":563,"type":20},"2030-09",{"name":39,"class":40},5,{"id":567,"slug":568,"hasResults":11,"nctId":569,"briefTitle":570,"officialTitle":570,"acronym":571,"eligibilityCriteria":572,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":573,"targetDuration":4,"studyType":216,"phases":4,"briefSummary":575,"conditions":576,"keywords":4,"overallStatus":63,"whyStopped":4,"lastUpdateSubmitDate":578,"lastUpdatePostDateStruct":579,"startDateStruct":581,"completionDateStruct":583,"leadSponsor":585,"locationsCount":72},"100573285","measurable-residual-disease-detection-using-tumor-informed-ctdna-surveillance-after-curative-intent-treatment-in-hpv-independent-squamous-cell-carcinoma-of-the-head-and-neck-100573285","NCT06744296","Measurable Residual Disease Detection Using Tumor-Informed ctDNA Surveillance After Curative-Intent Treatment in HPV-Independent Squamous Cell Carcinoma of the Head and Neck","MRD-DUCHESS","Inclusion Criteria:\n\n* Newly diagnosed AJCC 8th edition Stage III-IVB mucosal SCC of the head and neck, which includes tumors arising from the oral cavity, nasal cavity, paranasal sinuses, nasopharynx, oropharynx, hypopharynx, and larynx.\n* Available tissue for tumor-informed ctDNA panel creation.\n* Definitive treatment with standard of care surgery or chemoradiotherapy is planned to be administered at Massachusetts Eye and Ear Institute (MEEI) or within the Massachusetts General Hospital (MGH) Cancer Center (including but not limited to the Boston, Danvers, and Newton-Wellesley locations).\n\nExclusion Criteria:\n\n* Patients \\\u003C18 years of age\n* Patients receiving non-standard of care therapy as determined by the clinical investigator\n* Participants who have undergone prior surgical resection, excisional biopsy, radiation, and\u002For chemotherapy for the treatment of HNSCC. Prior incisional biopsies are permitted. Discrepant cases will be reviewed by study PI.\n* Participants who are receiving any investigational agents at the time of enrollment.\n* Participants with AJCC Stage IVC HNSCC, which includes patients with biopsy-confirmed distant metastatic HNSCC, including but not limited to metastatic spread to the lungs, bones, or liver.\n* Active non-HNSCC malignancy.\n* Active pregnancy during treatment.",{"count":574,"type":20},75,"This study will test the ability of a personalized blood test to determine which head and neck cancer patients will have a recurrence after treatment.",[577],"Squamous Cell Carcinoma of Head and Neck","2025-05-14",{"date":580,"type":33},"2025-05-18",{"date":582,"type":33},"2025-02-03",{"date":584,"type":20},"2029-01-06",{"name":39,"class":40},""]